Bio-Rad Laboratories (NYSE:BIO) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the ...
I rate Bio-Rad (BIO) with a buy rating. I start by mentioning that the low growth perspective is the negative aspect. For 2025, the company expects a 0.25% growth rate for its revenues, which might ...
Punishment of both Bio-Rad Laboratories, Inc. and Sartorius AG continued throughout the final stages of 2022. Bio-Rad Laboratories had an equally challenging Q3, setting up Q4 and FY22 numbers as key ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback